How are EXEL long call max profit and max loss calculated?

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the EXEL long call priced from the end-of-day chain at a 30-day expiry (ATM IV 37.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$405.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a EXEL long call?

The breakeven for the EXEL long call priced on this page is roughly $54.05 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EXEL market-implied 1-standard-deviation expected move is approximately 10.66%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current EXEL implied volatility affect this long call?

EXEL ATM IV is at 37.20% with IV rank near 40.53%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

EXEL Long Call Strategy

EXEL (Exelixis, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.

EXEL (Exelixis, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $12.89B, a trailing P/E of 15.90, a beta of 0.39 versus the broader market, a 52-week range of 33.76-51.48, average daily share volume of 2.8M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how EXEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.39 indicates EXEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on EXEL?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current EXEL snapshot

As of May 15, 2026, spot at $50.18, ATM IV 37.20%, IV rank 40.53%, expected move 10.66%. The long call on EXEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 98-day expiry.

Why this long call structure on EXEL specifically: EXEL IV at 37.20% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 10.66% (roughly $5.35 on the underlying). The 98-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EXEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on EXEL should anchor to the underlying notional of $50.18 per share and to the trader's directional view on EXEL stock.

EXEL long call setup

The EXEL long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EXEL near $50.18, the first option leg uses a $50.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EXEL chain at a 98-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EXEL shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$50.00	$4.05

EXEL long call risk and reward

Net Premium / Debit: -$405.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$405.00
Breakeven(s): $54.05
Risk / Reward Ratio: Unbounded

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

EXEL long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on EXEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$405.00
$11.10	-77.9%	-$405.00
$22.20	-55.8%	-$405.00
$33.29	-33.7%	-$405.00
$44.39	-11.5%	-$405.00
$55.48	+10.6%	+$142.98
$66.57	+32.7%	+$1,252.38
$77.67	+54.8%	+$2,361.78
$88.76	+76.9%	+$3,471.18
$99.86	+99.0%	+$4,580.57

When traders use long call on EXEL

Long calls on EXEL express a bullish thesis with defined risk; traders use them ahead of EXEL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

EXEL thesis for this long call

The market-implied 1-standard-deviation range for EXEL extends from approximately $44.83 on the downside to $55.53 on the upside. A EXEL long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current EXEL IV rank near 40.53% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on EXEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, EXEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EXEL-specific events.

EXEL long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EXEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EXEL alongside the broader basket even when EXEL-specific fundamentals are unchanged. Long-premium structures like a long call on EXEL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current EXEL chain quotes before placing a trade.

Frequently asked questions

What is a long call on EXEL?: A long call on EXEL is the long call strategy applied to EXEL (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With EXEL stock trading near $50.18, the strikes shown on this page are snapped to the nearest listed EXEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are EXEL long call max profit and max loss calculated?: Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the EXEL long call priced from the end-of-day chain at a 30-day expiry (ATM IV 37.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$405.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a EXEL long call?: The breakeven for the EXEL long call priced on this page is roughly $54.05 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EXEL market-implied 1-standard-deviation expected move is approximately 10.66%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on EXEL?: Long calls on EXEL express a bullish thesis with defined risk; traders use them ahead of EXEL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current EXEL implied volatility affect this long call?: EXEL ATM IV is at 37.20% with IV rank near 40.53%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.